aTyr Pharma reports paper showing anti-fibrotic effects of ATYR0101 in lung model
ATYR•aTyr Pharma reported that Journal of Biological Chemistry data showed ATYR0101 reduced collagen content and Ashcroft score in a bleomycin lung fibrosis model, outperforming the nintedanib control. The program remains in IND-enabling studies, with plans to enter the clinic in 2027.
1. Lung model findings
aTyr Pharma published Journal of Biological Chemistry data showing anti-fibrotic activity for ATYR0101, a DARS-derived fusion protein. The treatment targets LTBP-1 to trigger myofibroblast apoptosis, with activity dependent on active TGF-β; in a bleomycin lung fibrosis model, it reduced collagen content and Ashcroft score, outperforming the nintedanib control. The program remains in IND-enabling studies, with plans to enter the clinic in 2027.
